Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Revenue | revenue | 2.26B | 2.91% |
| Income before provision for taxes on income | profit | 758.00M | -1.94% |
| Cost of sales | cost | 641.00M | 3.72% |
| Selling, general and administrative expenses | cost | 588.00M | 2.44% |
| Research and development expense (excluding acquired in process cost) | cost | 180.00M | 11.11% |
| Interest expense, net of capitalized interest | cost | 62.00M | 14.81% |
| Amortization of intangible assets | cost | 31.00M | -3.12% |
| Total restructuring charges and certain acquisition and divestiture-related costs | cost | 22.00M | |
| Net income | profit | 601.00M | -0.17% |
| Provision for taxes on income | cost | 157.00M | -8.19% |
| Net income attributable to zoetis inc. | profit | 601.00M | -0.17% |
| Segment | Value | YoY |
|---|---|---|
| International | 1.15B | 16.65% |
| United States | 1.09B | -7.86% |
| Others | 23.00M | -23.33% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 1.09B | -7.86% |
| Others | 1.17B | 15.47% |
| Segment | Value | YoY |
|---|---|---|
| Parasiticides | 586.00M | 2.45% |
| Vaccines | 519.00M | 18.22% |
| Dermatology | 349.00M | -7.92% |
| Anti-infective Products | 241.00M | 1.26% |
| Pain & Sedation | 203.00M | -1.93% |
| Other Pharmaceuticals | 158.00M | 0.00% |
| Animal Health Diagnostics | 117.00M | 12.50% |
| Other Non Pharmaceuticals | 66.00M | -7.04% |
| Contract Manufacturing and Human Health Diagnostics | 23.00M | -23.33% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Inventories | assets | 2.55B | |
| Cash and cash equivalents | assets | 1.94B | |
| Accounts receivable, after allowance for credit loss, current | assets | 1.51B | |
| Other current assets | assets | 477.00M | |
| Total current assets | assets | 6.47B | |
| Property, plant and equipment, less accumulated depreciation of $3,002 in 2026 and $2,935 in 2025 | assets | 3.72B | |
| Goodwill | assets | 2.78B | |
| Identifiable intangible assets, less accumulated amortization | assets | 959.00M | |
| Noncurrent deferred tax assets | assets | 591.00M | |
| Other noncurrent assets | assets | 351.00M | |
| Operating lease right-of-use assets | assets | 282.00M | |
| Assets | assets | 15.15B | |
| Liabilities | liabilities | 11.92B | |
| Total equity | liabilities | 3.23B | |
| Long-term debt, net of discount and issuance costs | liabilities | 9.04B | |
| Total current liabilities | liabilities | 2.05B | |
| Other taxes payable | liabilities | 281.00M | |
| Other noncurrent liabilities | liabilities | 219.00M | |
| Operating lease liabilities | liabilities | 193.00M | |
| Noncurrent deferred tax liabilities | liabilities | 130.00M | |
| Total zoetis inc. equity | equity | 3.23B | |
| Treasury stock, value | equity | 11.29B | |
| Accumulated other comprehensive loss | equity | 772.00M | |
| Accrued expenses | liabilities | 751.00M | |
| Accounts payable | liabilities | 507.00M | |
| Accrued compensation and related items | liabilities | 239.00M | |
| Dividends payable | liabilities | 224.00M | |
| Income taxes payable | liabilities | 211.00M | |
| Other current liabilities | liabilities | 121.00M | |
| Aggregate | equity | 15.29B | |
| Retained earnings | equity | 14.18B | |
| Additional paid-in capital | equity | 1.10B | |
| Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 420,348,495 and 424,927,535 shares outstanding at march 31, 2026, and december 31, 2025, respectively | equity | 5.00M |
| Item | Value |
|---|---|
| Net income | 601.00M |
| Depreciation and amortization expense | 119.00M |
| Other tax accounts, net | 73.00M |
| Accounts payable | 62.00M |
| Deferred taxes | 34.00M |
| Share-based compensation expense | 25.00M |
| Provision for losses on inventory | 13.00M |
| Other noncash income (expense) | 3.00M |
| Cash received from / (payments to) settle derivative instruments | -3.00M |
| Net gain on sale of assets | -6.00M |
| Increase (decrease) in other operating assets | -66.00M |
| Increase (decrease) in accounts receivable | -106.00M |
| Increase (decrease) in inventories | -114.00M |
| Other liabilities | -234.00M |
| Item | Value |
|---|---|
| Payments for (proceeds from) hedge, investing activities | 16.00M |
| Net proceeds from sale of assets | 10.00M |
| Payment for (proceeds from) other investing activity | -1.00M |
| Payments to acquire investments | -2.00M |
| Payments to acquire property, plant, and equipment | -110.00M |
| Item | Value |
|---|---|
| Other financing activities | -3.00M |
| Share-based compensation-related proceeds, net of taxes paid on withholding shares | -7.00M |
| Payments of ordinary dividends | -224.00M |
| Payments for the repurchase of common stock | -606.00M |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 2.45B |
| Cash and cash equivalents, end of period | 1.94B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support